Amarex Taiwan is an affiliate of Amarex Clinical Research,

a full-service, international CRO with extensive experience successfully performing clinical studies across all phases of research and

discovery, development, validation and approval.



  • LinkedIn Social Icon
  • Facebook
  • Twitter
  • YouTube
16 September 2020

2020 Bio Innovation Conference | Oct. 5-6

Dr. Kazem Kazempour, Amarex President & CEO, will present virtually at Bio Innovation on October 6. He will discuss Business Resiliency for the Unexpected and Expected. Amarex will also exhibit at this conference.

10 September 2020

Amarex Receives SMP Letter from TFDA for an Oncology Drug Clinical Trial Treating Pancreatic Cancer

Amarex Taiwan, LLC, an NSF International company announces today that earlier this week they received a study may proceed (SMP) letter from the Taiwan Food & Drug Administration (TFDA) to conduct the first in human clinical trial of RP-72 in Taiwan.

04 September 2020

2020 KoNECT-MOHW-MFDS International Conference Virtual | Sep 9-11 

Amarex Taiwan, LLC, an NSF International company, is pleased to announce exhibiting at 2020 Korea National Enterprise for Clinical Trials (KoNECT) Ministry of Health and Welfare (MOHW) Ministry of Food and Drug Safety (MFDS) International Conference Virtual, held September 09-11.

02 September 2020

Amarex in the Fight Against COVID-19

In early March, Amarex Taiwan, LLC, an NSF International company began work on a potential treatment for Coronavirus Disease 2019. Since then, Amarex has helped 16 companies on 32 separate projects for COVID-19 products.

Recommended by the people who matter most: our clients.

Chief Medical Officer

A Maryland Biotech Company

We have worked with Amarex on numerous projects and they consistently deliver high quality reliable service by leveraging a broad array of clinical and regulatory expertise. What sets them apart from other CROs is a creative entrepreneurial approach to drug development. They go beyond the technical aspects of clinical trial development and work with the sponsor to drive value and increase chances for success.



Chief Technical Officer

A Canadian-based Infectious Diseases Organization

[Thank you to the team at Amarex] for the statistical support which proved to be invaluable and completely accurate in the final review by FDA. The cornerstone of this milestone achievement was the data from the clinical study, including the limit of detection study, and we came through [all FDA reviews with solid outcomes throughout]. From all of us here, a sincere thank you and well done to all at Amarex who worked on this project. We look forward to working with you again as we apply the successful platform to other diagnostic device developments in the future.



2F., No.19-10, Sanchong Rd., Nangang District, Taipei 115, TAIWAN |  +886-2-26553391